ALFA Finder| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 5.3 | 2.5 | 1.3 |
| Total income | 5.3 | 2.5 | 1.3 |
| Profit before exceptional items & tax | 0.2 | 0.1 | 0.0 |
| Profit before tax | 0.2 | 0.1 | 0.0 |
| Net profit | 0.1 | 0.1 | 0.0 |
| Operating margin | 3.8% | 4.0% | 0.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, quarter on quarter | +0.00% |
|---|---|
| Revenue, year on year | +307.70% |
BSE results filing, NSE: VENMAX. Figures extracted from the filing.
Venmax Drugs & Pharmaceuticals Ltd: key numbers
- Share price
- ₹14.32
- Market cap
- ₹12.58 Cr
- Revenue (annual)
- ₹8.02 Cr
- Net profit (annual)
- ₹0.25 Cr
- P/E (TTM)
- 44.9×Sector 43.8×
- Promoter holding
- 10.46%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Venmax Drugs & Pharmaceuticals Ltd
All →Venmax Drugs & Pharmaceuticals Other Announcement
Venmax Drugs confirmed no deviation in using preferential warrant proceeds for the quarter ended September 2026. The statement was reviewed by the Audit Committee.
Venmax Drugs & Pharmaceuticals Board Meeting Date
Venmax Drugs and Pharmaceuticals will hold a board meeting on November 12, 2026 to consider unaudited standalone results for the quarter ended September 30, 2026. The trading window stays closed until November 14, 2026.
Venmax Drugs & Pharmaceuticals Acquisition
Venmax Drugs' shareholders met on 24 October 2026 under an NCLT order to approve an amalgamation with Hatri Pharma. Voting results await the scrutinizer's report.
Venmax Drugs & Pharmaceuticals Other Announcement
The company filed its quarterly shareholding pattern under Regulation 31(1)(b) of the SEBI LODR Regulations for the quarter ended September 30, 2026.
Venmax Drugs & Pharmaceuticals Annual General Meeting
Venmax Drugs and Pharmaceuticals held its 37th Annual General Meeting on September 26, 2026. Shareholders considered the financial statements and various directorship appointments.
Venmax Drugs & Pharmaceuticals Acquisition
Venmax Drugs and Pharmaceuticals Limited announced an NCLT-convened meeting of equity shareholders on October 24, 2026, to consider the proposed merger with Hatri Pharma Private Limited.